Such alternative approaches could include optimizing insulin dose titration or exploring the use of SGLT-2 inhibitors or GLP-1 agonists, which have demonstrated efficacy in the management of type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.